Michael Gomendoza, MD
Internal Medicine · Coralville, IANPI 1174637110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,275 and has fallen 94.6% since, to $69 in 2024. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$237
- AstraZeneca$226
- Johnson & Johnson$224
- Pfizer$218
- Amgen$200
- Boehringer Ingelheim$162
- plus $648 from 12 others
What the payments were for
- Food & beverage$1,915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $237 |
| AstraZeneca | 9 | $226 |
| Johnson & Johnson | 15 | $224 |
| Pfizer | 20 | $218 |
| Amgen | 13 | $200 |
| Boehringer Ingelheim | 11 | $162 |
| GSK | 8 | $136 |
| Amarin Pharma, Inc. | 6 | $99 |
| Lilly USA, LLC | 6 | $90 |
| Kowa Pharmaceuticals America, Inc. | 5 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Novartis | 3 | $42 |
| Genentech USA, Inc. | 2 | $37 |
| Corcept Therapeutics | 2 | $36 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Digital Diagnostics Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Dermira, Inc. | 1 | $17 |
How this compares
$1,915 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 128 | $118,376 |
| TrulicityDulaglutide | 39 | $38,258 |
| EliquisApixaban | 30 | $35,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $31,911 |
| XareltoRivaroxaban | 26 | $28,298 |
| FarxigaDapagliflozin Propanediol | 20 | $23,138 |
| OzempicSemaglutide | 19 | $21,932 |
| Spiriva HandihalerTiotropium Bromide | 22 | $18,616 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $13,120 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $10,052 |
| SavellaMilnacipran Hcl | 13 | $9,873 |
| JanuviaSitagliptin Phosphate | 14 | $8,955 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,120 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,276 |
| Rosuvastatin Calcium | 426 | $5,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $162 | $118,376128 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $136 | $45,03162 claims |
| Lilly USA, LLCTrulicity | $90 | $38,25839 claims |
| PfizerEliquis | $218 | $35,82430 claims |
| Johnson & JohnsonXarelto | $224 | $28,29826 claims |
| AstraZenecaFarxiga, Symbicort | $226 | $27,86741 claims |
| AbbVieSavella, Synthroid | $237 | $12,97954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Coralville
- Jessica JacobsonCoralville$4K
- Carol Ann TanCoralville$2K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.